Literature DB >> 11029748

Angiogenesis in the thyroid gland.

J D Ramsden1.   

Abstract

Angiogenesis is the mechanism of blood vessel formation after the first few days of embryogenesis, and is essential for all tissue growth. In adults, angiogenesis occurs in the thyroid during disease processes including goitre, Graves' disease, thyroiditis and cancer. The molecular mechanisms controlling angiogenesis are becoming clearer, and therapy targeting these processes is coming closer to clinical fruition. Both promoters and inhibitors of angiogenesis have been identified in the thyroid, including vascular endothelial growth factor (VEGF), fibroblast growth factor, and thrombospondin. This commentary will review the understanding of the control of angiogenesis within the context of the thyroid gland, and review the pre-eminent role of VEGF as the angiogenic signal from the follicular cells to the endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029748     DOI: 10.1677/joe.0.1660475

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  34 in total

1.  A comparison of radionuclide thyroid angiography, (99m)Tc-MIBI scintigraphy and power Doppler ultrasonography in the differential diagnosis of solitary cold thyroid nodules.

Authors:  Koray Demirel; Ozlem Kapucu; Cem Yücel; Hakan Ozdemir; Göksun Ayvaz; Ferit Taneri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-01       Impact factor: 9.236

Review 2.  Anticancer Drug-induced Thyroid Dysfunction.

Authors:  Saptarshi Bhattacharya; Alpesh Goyal; Parjeet Kaur; Randeep Singh; Sanjay Kalra
Journal:  Eur Endocrinol       Date:  2020-02-04

3.  Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS).

Authors:  Xi Wei; Ying Li; Sheng Zhang; Gao Ming
Journal:  Tumour Biol       Date:  2014-04-01

4.  AcSDKP: a new potential marker of malignancy of the thyroid gland.

Authors:  Michal Kusinski; Joanna Wdzieczak-Bakala; Jian-Miao Liu; Jerome Bignon; Krzysztof Kuzdak
Journal:  Langenbecks Arch Surg       Date:  2006-01-18       Impact factor: 3.445

Review 5.  Recent insights into the cell biology of thyroid angiofollicular units.

Authors:  Ides M Colin; Jean-François Denef; Benoit Lengelé; Marie-Christine Many; Anne-Catherine Gérard
Journal:  Endocr Rev       Date:  2013-01-24       Impact factor: 19.871

Review 6.  Antiangiogenic treatments and mechanisms of action in renal cell carcinoma.

Authors:  Sylvie Négrier; Eric Raymond
Journal:  Invest New Drugs       Date:  2011-05-15       Impact factor: 3.850

7.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

8.  Genetic interaction analysis of VEGF-A rs3025039 and VEGFR-2 rs2071559 identifies a genetic profile at higher risk to develop nodular goiter.

Authors:  A Molinaro; P Orlandi; F Niccolai; P Agretti; G De Marco; E Ferrarini; C Di Cosmo; P Vitti; P Piaggi; T Di Desidero; G Bocci; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2019-08-02       Impact factor: 4.256

9.  Iodine deficiency induces a thyroid stimulating hormone-independent early phase of microvascular reshaping in the thyroid.

Authors:  Anne-Catherine Gérard; Sylvie Poncin; Bertrand Caetano; Pierre Sonveaux; Jean-Nicolas Audinot; Olivier Feron; Ides M Colin; Fabrice Soncin
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

10.  The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.

Authors:  Joanna Klubo-Gwiezdzinska; Roman Junik; Ewa Kopczynska; Olga Juraniec; Hanna Kardymowicz
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.